These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36101479)

  • 21. Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.
    Wenk BM; Mbunkah HA; Nsanwe NN; Mbu ET; Besong LM; Sama BA; Orock E; Leemann C; Metzner KJ
    J Antimicrob Chemother; 2021 Jan; 76(1):124-129. PubMed ID: 32954411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons.
    Bailey AJ; Rhee SY; Shafer RW
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):736-743. PubMed ID: 33683148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.
    Abdullahi A; Kida IM; Maina UA; Ibrahim AH; Mshelia J; Wisso H; Adamu A; Onyemata JE; Edun M; Yusuph H; Aliyu SH; Charurat M; Abimiku A; Abeler-Dorner L; Fraser C; Bonsall D; ; Kemp SA; Gupta RK
    J Antimicrob Chemother; 2023 Aug; 78(8):2000-2007. PubMed ID: 37367727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
    Hachiya A; Kirby KA; Ido Y; Shigemi U; Matsuda M; Okazaki R; Imamura J; Sarafianos SG; Yokomaku Y; Iwatani Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low level of HIV-1C integrase strand transfer inhibitor resistance mutations among recently diagnosed ART-naive Ethiopians.
    Kiros M; Tefera DA; Andualem H; Geteneh A; Tesfaye A; Woldemichael TS; Kidane E; Alemayehu DH; Maier M; Mihret A; Abegaz WE; Mulu A
    Sci Rep; 2023 Apr; 13(1):6546. PubMed ID: 37085698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy.
    Huik K; Hill S; George J; Pau A; Kuriakose S; Lange CM; Dee N; Stoll P; Khan M; Rehman T; Rehm CA; Dewar R; Grossman Z; Maldarelli F
    AIDS; 2022 Nov; 36(13):1835-1840. PubMed ID: 35848510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary resistance to integrase strand-transfer inhibitors in Europe.
    Casadellà M; van Ham PM; Noguera-Julian M; van Kessel A; Pou C; Hofstra LM; Santos JR; Garcia F; Struck D; Alexiev I; Bakken Kran AM; Hoepelman AI; Kostrikis LG; Somogyi S; Liitsola K; Linka M; Nielsen C; Otelea D; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Staneková D; Stanojevic M; Van Laethem K; Zidovec Lepej S; Clotet B; Boucher CA; Paredes R; Wensing AM;
    J Antimicrob Chemother; 2015 Oct; 70(10):2885-8. PubMed ID: 26188038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
    Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
    J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naive and Treatment-Experienced HIV Patients in South Korea.
    Jeong W; Jung IY; Choi H; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Kim JM; Choi JY
    AIDS Res Hum Retroviruses; 2019 Feb; 35(2):213-216. PubMed ID: 30229661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.
    Armenia D; Santoro MM; Charpentier C; Bertoli A; Forbici F; Calvez V; Descamps D; Ceccherini-Silberstein F; Marcelin AG; Flandre P
    J Antimicrob Chemother; 2023 Jun; 78(6):1415-1422. PubMed ID: 37258034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.
    Acharya A; Tagny CT; Mbanya D; Fonsah JY; Nchindap E; Kenmogne L; Jihyun M; Njamnshi AK; Kanmogne GD
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106437
    [No Abstract]   [Full Text] [Related]  

  • 33. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.
    Abram ME; Ram RR; Margot NA; Barnes TL; White KL; Callebaut C; Miller MD
    PLoS One; 2017; 12(2):e0172206. PubMed ID: 28212411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Rinke de Wit TF; Paredes R
    J Antimicrob Chemother; 2018 May; 73(5):1167-1172. PubMed ID: 29462322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary resistance to integrase inhibitors in Shenzhen.
    Zhu Y; Huang Y; Zheng C; Tang J; Zeng G; Xie W; Wang H; Zhang L; Liu S; Zhang Y; Tan W; Tan J; Jiang L; He Y; Xu L; Yang Z; Zhao J
    J Antimicrob Chemother; 2023 Feb; 78(2):546-549. PubMed ID: 36585770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
    Marcelin AG; Charpentier C; Bellecave P; Abdi B; Chaix ML; Ferre V; Raymond S; Fofana D; Bocket L; Mirand A; Le Guillou-Guillemette H; Montes B; Amiel C; Pallier C; Fafi-Kremer S; De Monte A; Alessandri-Gradt E; Scholtes C; Maillard A; Jeulin H; Bouvier-Alias M; Roussel C; Dos Santos G; Signori-Schmuck A; Dina J; Vallet S; Stefic K; Soulié C; Calvez V; Descamps D; Flandre P;
    J Antimicrob Chemother; 2021 Aug; 76(9):2400-2406. PubMed ID: 34100068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
    Margot NA; Ram RR; White KL; Abram ME; Callebaut C
    J Med Virol; 2019 Dec; 91(12):2188-2194. PubMed ID: 31389026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
    Kirichenko A; Lapovok I; Baryshev P; van de Vijver DAMC; van Kampen JJA; Boucher CAB; Paraskevis D; Kireev D
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32752001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.
    Seatla KK; Choga WT; Mogwele M; Diphoko T; Maruapula D; Mupfumi L; Musonda RM; Rowley CF; Avalos A; Kasvosve I; Moyo S; Gaseitsiwe S
    PLoS One; 2019; 14(11):e0224292. PubMed ID: 31751353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural effects of HIV-1 subtype C integrase mutations on the activity of integrase strand transfer inhibitors in South African patients.
    Mbhele N; Gordon M
    J Biomol Struct Dyn; 2022; 40(23):12546-12556. PubMed ID: 34488561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.